Hypercoagulability and the Management of Anticoagulant Therapy in Surgical Patients: Review and Recommendations

Abstract

Get full access to this article

View all access options for this article.

References

Donaldson

. Hypercoagulable states in patients with peripheral vascular disease. In: Whittemore

, ed. Advances in Vascular Surgery. vol. 1. St. Louis, Mosby Year Book, 1993: 227–242.

Bell

Bilazarian

. Coagulation, coagulation disorders, and antithrombotic therapy. In: Young

Graor

Olin

, eds. Peripheral Vascular Diseases. St. Louis, Mosby Year Book, 1991: 71–93.

Clouse

Comp

. The regulation of hemostasis: The protein C system. N Engl J Med 1986; 314: 1298–1304.

Esmon

. Protein C and the endothelium. Semin Thromb Hemost 1988; 14: 210–215.

Donaldson

Belkin

Whittemore

. Impact of activated protein C resistance on general vascular surgical patients. J Vasc Surg 1997; 25: 1054–1060.

Griffin

Evart

Wideman

. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989–1993.

Dahlback

Carlsson

Svensson

. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004–1008.

DeStefano

Finazzi

Mannucci

. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531–3544.

Bertina

Koeleman

Koster

. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.

10.

Zoller

Dahlback

. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536–1538.

11.

Halbmayer

Haushofer

Schon

. The prevalence of poor anticoagulant response to activated protein C among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51–57.

12.

Cushman

Bhushan

Bovill

. Plasma resistance to activated protein C in venous and arterial thrombosis. (Letter) Thromb Haemost 1994; 72: 647.

13.

Ouriel

Green

DeWeese

. Activated protein C resistance: Prevalence and implications in peripheral vascular disease. J Vasc Surg 1996; 23: 46–52.

14.

Dahlback

. Resistance to activated protein C caused by the factor V R506 Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483–488.

15.

Ridker

Hennekens

Lindpaintner

. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–917.

16.

Griffin

Heeb

Schwarz

. Plasma protein S deficiency and thromboembolic disease. Prog Hematol 1987; 15: 39–49.

17.

Marciniak

Farley

de Simone

. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219–221.

18.

Cosgriff

Bishop

Hershgold

. Familial antithrombin III deficiency: Its natural history, genetics, diagnosis, and treatment. Medicine (Baltimore) 1983; 62: 209–220.

19.

Bauer

Rosenberg

. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol 1991; 28: 10–18.

20.

Hughes

. The antiphospholipid syndrome: Ten years on. Lancet 1993; 342: 341–344.

21.

Esmon

Smirnov

Esmon

. Lupus anticoagulants and thrombosis: The role of phospholipids. Haematologica 1997; 82: 474–477.

22.

Esmon

Smirnov

Esmon

. Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemost 1997; 78: 79–82.

23.

Stratta

Canavese

Ferrero

. Guidelines for looking at the antiphospholipid antibodies in systemic lupus erythematosus. Nephron 1997; 76: 400–405.

24.

Bazzan

Tamponi

Vaccarino

. Natural and acquired inhibitors of hemostasis in selected outpatients with venous thromboembolic disease. Haematologica 1997; 82: 420–422.

25.

Creagh

Malia

Cooper

. Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss. J Clin Pathol 1991; 44: 45–47.

26.

Nitecki

Brenner

Hoffman

. Lower limb ischaemia in primary antiphospholipid syndrome. Eur J Vasc Surg 1993; 7: 414–419.

27.

Prieto

Suki

. Frequent hemodialysis graft thrombosis: Association with antiphospholipid antibodies. Am J Kidney Dis 1994; 23: 587–590.

28.

Hirsh

Fuster

. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994; 89: 1449–1468.

29.

Hull

Raskob

Hirsh

. Continuous intravenous heparin compared with subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109–1114.

30.

Pini

Pattacini

Quintavalla

. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis: A randomized clinical trial. Thromb Haemost 1992; 64: 222–226.

31.

Glazier

Crowell

. Randomized prospective trial of continuous vs. intermittent heparin therapy. JAMA 1976; 236: 1365–1367.

32.

Robinson

McLean

Greaves

. Subcutaneous vs. intravenous administration of heparin in the treatment of deep vein thrombosis: Which do patients prefer? A randomized crossover study. Postgrad Med J 1993; 69(808): 115–167.

33.

Kakkar

Boeckl

Boneu

. Efficacy and safety of a low molecular weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 1997; 21: 2–9.

34.

Hull

Raskob

Pineo

. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975–982.

35.

Meyer

Brenot

Pacouret

. Subcutaneous low molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute nonmassive pulmonary embolism: An open randomized pilot study. Thromb Haemost 1995; 74: 1432–1435.

36.

Levine

Gent

Hirsh

. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–681.

37.

Kearon

. Drug trials that have influenced our practice in the treatment of venous thromboembolism. Thromb Haemost 1997; 78: 553–557.

38.

Pini

Aiello

Manotti

. Low molecular weight heparin versus warfarin in the prevention of recurrence after deep vein thrombosis. Thromb Haemost 1994; 72: 191–197.

39.

Samama

Gigou

III . Low molecular weight heparin versus unfractionated heparin in femorodistal reconstructive surgery: A multicentre open randomized study. Ann Vasc Surg 1995; 9(Suppl): S45–S53.

40.

Edmonson

Cohen

Das

. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994; 344: 914–918.

41.

Hausberg

Stober

Heidenreich

. Arterial embolism and thrombocytopenia during heparin therapy. Schweiz Rundsch Med Prax 1993; 82: 668–671.

42.

Bentley

Kakkar

Scully

. An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177–187.

43.

Magnani

. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran. Thromb Hemost 1993; 70: 554–561

44.

Hirsh

Fuster

. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994; 89: 1469–1480.

45.

Pescatore

Horellou

. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and the late onset of thrombosis. Thromb Haemost 1993; 69: 311–315.

46.

Fennerty

Dolben

Petal

. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984; 288: 1268–1270.

47.

Zauber

Stark

. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104: 659–660.